Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 5/20 | 0.33 |
| ▸ | MAOB | P27338 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31408750 | 0.89 | LIPG (0.51) | LPLLIPGANPEPLAP3SMN1; SMN2 | |
| SCHEMBL18471018 | 0.82 | ALDH1A1 (0.35) | APLNRSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL25172268 | 0.81 | LMNA (0.36) | APLNRMAOAMAOBKMT2ALMNA | |
| SCHEMBL6236173 | 0.79 | LPL (0.42) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL6236171 | 0.79 | LPL (0.42) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL6236165 | 0.79 | LPL (0.42) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL17226547 | 0.79 | LPL (0.45) | LPLLIPGF2PRSS1SMN1; SMN2 | |
| SCHEMBL31408747 | 0.79 | C1S (0.40) | SMN1; SMN2MEN1KMT2AATMNPSR1 | |
| SCHEMBL30502749 | 0.79 | CES2 (0.42) | MAOAMAOBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL25168903 | 0.79 | CES2 (0.42) | MAOAMAOBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ENANTA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12358921-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-1963312-B1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
| WO-2014100065-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-7838676-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1963312-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070173521-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007061930-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | LPL 2073/4885LIPG 2834/4885ANPEP 2838/4885 |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | LPL 4183/4885LIPG 3961/4885ANPEP 2054/4885 |
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | LPL 2106/4885LIPG 3053/4885ANPEP 3103/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | LPL 3897/4885LIPG 2743/4885ANPEP 2654/4885 |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | LPL 3062/4885LIPG 2292/4885ANPEP 1469/4885 |
| US-12358921-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | LPL 2002/4885LIPG 2271/4885ANPEP 310/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | LPL 4871/4885LIPG 3592/4885ANPEP 2813/4885 |
| US-20070173521-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | LPL 1183/4885LIPG 1471/4885ANPEP 106/4885 |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ACE, HPRT1, ACE2 | LPL 2002/4885LIPG 2271/4885ANPEP 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.